Inhibition of FAAH and activation of PPAR: New approaches to the treatment of cognitive dysfunction and drug addiction

Pharmacology and Therapeutics

Volumn 138, Issue 1, 2013, Pages 84-102

  Panlilio, Leigh V ^a   Justinova, Zuzana ^a,b   Goldberg, Steven R ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Animal models; Behavior; CB1 receptors; Drug abuse; Endocannabinoid system; Keywords; Nuclear receptors

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ALCOHOL; AM 1346; AM 3506; AM 4054; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DEXANABINOL; ENDOCANNABINOID; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; FATTY ACID BINDING PROTEIN; METHANANDAMIDE; NICOTINE; NOLADIN ETHER; O 1812; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PF 04457845; RIMONABANT; UNCLASSIFIED DRUG; UNINDEXED DRUG; URB 694; VIRODHAMINE;

ALCOHOL WITHDRAWAL; ALCOHOLISM; BASOLATERAL AMYGDALA; CHRONIC STRESS; COGNITION; COGNITIVE DEFECT; DNA POLYMORPHISM; DRUG ABUSE; DRUG SELF ADMINISTRATION; DRUG TOLERANCE; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; KNOCKOUT MOUSE; LEARNING; LIGAND BINDING; MEMORY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RELAPSE; REVIEW; REWARD; RHESUS MONKEY; SMOKING CESSATION; SQUIRREL MONKEY; WITHDRAWAL SYNDROME;

AMIDOHYDROLASES; ANIMALS; COGNITION DISORDERS; HUMANS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; SUBSTANCE-RELATED DISORDERS;

EID: 84875230670     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2013.01.003     Document Type: Review

References (331)

1. V. Abadji, S. Lin, G. Taha, G. Griffin, L.A. Stevenson, and R.G. Pertwee (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability J Med Chem 37 1994 1889 1893
2. M.E. Abood, and B.R. Martin Neurobiology of marijuana abuse Trends Pharmacol Sci 13 1992 201 206
3. M.D. Aceto, S.M. Scates, J.A. Lowe, and B.R. Martin Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A Eur J Pharmacol 282 1995 R1 R2
4. M.D. Aceto, S.M. Scates, J.A. Lowe, and B.R. Martin Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal J Pharmacol Exp Ther 278 1996 1290 1295
5. M.D. Aceto, S.M. Scates, R.K. Razdan, and B.R. Martin Anandamide, an endogenous cannabinoid, has a very low physical dependence potential J Pharmacol Exp Ther 287 1998 598 605
6. P. Adamczyk, A.C. McCreary, E. Przegalinski, P. Mierzejewski, P. Bienkowski, and M. Filip The effects of fatty acid amide hydrolase inhibitors on maintenance of cocaine and food self-administration and on reinstatement of cocaine-seeking and food-taking behavior in rats J Physiol Pharmacol 60 2009 119 125
7. A. Agrawal, and M.T. Lynskey Candidate genes for cannabis use disorders: findings, challenges and directions Addiction 104 2009 518 532
8. S. Agurell, M. Halldin, J.E. Lindgren, A. Ohlsson, M. Widman, and H. Gillespie Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man Pharmacol Rev 38 1986 21 43
9. K. Ahn, D.S. Johnson, M. Mileni, D. Beidler, J.Z. Long, and M.K. McKinney Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain Chem Biol 16 2009 411 420
10. T. Alici, and J.B. Appel Increasing the selectivity of the discriminative stimulus effects of delta 9-tetrahydrocannabinol: complete substitution with methanandamide Pharmacol Biochem Behav 79 2004 431 437
11. L. Alvarez-Jaimes, I. Polis, and L.H. Parsons Attenuation of cue-induced heroin-seeking behavior by cannabinoid CB1 antagonist infusions into the nucleus accumbens core and prefrontal cortex, but not basolateral amygdala Neuropsychopharmacology 33 2008 2483 2493
12. K. Anggadiredja, M. Nakamichi, T. Hiranita, H. Tanaka, Y. Shoyama, and S. Watanabe Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade Neuropsychopharmacology 29 2004 1470 1478
13. A. Arevalo-Martin, D. Garcia-Ovejero, O. Gomez, A. Rubio-Araiz, B. Navarro-Galve, and C. Guaza CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies Br J Pharmacol 153 2008 216 225
14. M. Arnone, J. Maruani, F. Chaperon, M.H. Thiebot, M. Poncelet, and P. Soubrie Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors Psychopharmacology (Berl) 132 1997 104 106
15. J.C. Ashton, and M. Glass The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration Curr Neuropharmacol 5 2007 73 80
16. N. Ballon, S. Leroy, C. Roy, M.C. Bourdel, A. Charles-Nicolas, and M.O. Krebs (AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population Pharmacogenomics J 6 2006 126 130
17. G.D. Barish, V.A. Narkar, and R.M. Evans PPAR delta: a dagger in the heart of the metabolic syndrome J Clin Invest 116 2006 590 597
18. C. Barnes, S.R. Goldberg, and Z. Justinova Cannabinoid CB1 receptors are not involved in the discriminative-stimulus effects of methamphetamine or cocaine in rats Neuroscience Meeting Planner Atlanta, GA: Society for Neuroscience, 2006 Online Program No. 689.22 2006
19. B.S. Basavarajappa, T.B. Cooper, and B.L. Hungund Chronic ethanol administration down-regulates cannabinoid receptors in mouse brain synaptic plasma membrane Brain Res 793 1998 212 218
20. B.S. Basavarajappa, and B.L. Hungund Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N- arachidonoylphosphatidylethanolamine in SK-N-SH cells J Neurochem 72 1999 522 528
21. B.S. Basavarajappa, M. Saito, T.B. Cooper, and B.L. Hungund Stimulation of cannabinoid receptor agonist 2-arachidonylglycerol by chronic ethanol and its modulation by specific neuromodulators in cerebellar granule neurons Biochim Biophys Acta 1535 2000 78 86
22. B.S. Basavarajappa, R. Yalamanchili, B.F. Cravatt, T.B. Cooper, and B.L. Hungund Increased ethanol consumption and preference and decreased ethanol sensitivity in female FAAH knockout mice Neuropharmacology 50 2006 834 844
23. V. Bassareo, M.A. De Luca, and G. Di Chiara Differential impact of pavlovian drug conditioned stimuli on in vivo dopamine transmission in the rat accumbens shell and core and in the prefrontal cortex Psychopharmacology (Berl) 191 2007 689 703
24. A. Benyamina, O. Kebir, L. Blecha, M. Reynaud, and M.O. Krebs CNR1 gene polymorphisms in addictive disorders: a systematic review and a meta-analysis Addict Biol 16 2011 1 6
25. F. Bequet, F. Uzabiaga, M. Desbazeille, P. Ludwiczak, M. Maftouh, and C. Picard CB1 receptor-mediated control of the release of endocannabinoids (as assessed by microdialysis coupled with LC/MS) in the rat hypothalamus Eur J Neurosci 26 2007 3458 3464
26. J. Bergman, S. Olajire, A. Makriyannis, Z. Justinova, and S.R. Goldberg Discriminative-stimulus and reinforcing effects of FAAH inhibitors in CB-1 trained subjects FASEB J 25 2011 796.4
27. Y.A. Blednov, B.F. Cravatt, S.L. Boehm, D. Walker, and R.A. Harris Role of endocannabinoids in alcohol consumption and intoxication: studies of mice lacking fatty acid amide hydrolase Neuropsychopharmacology 32 2007 1570 1582
28. S.Y. Boctor, J.L. Martinez Jr., W. Koek, and C.P. France The cannabinoid CB1 receptor antagonist AM251 does not modify methamphetamine reinstatement of responding Eur J Pharmacol 571 2007 39 43
29. M. Bouaboula, S. Hilairet, J. Marchand, L. Fajas, G. Le Fur, and P. Casellas Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation Eur J Pharmacol 517 2005 174 181
30. D. Braida, S. Iosue, S. Pegorini, and M. Sala Delta9- tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats Eur J Pharmacol 506 2004 63 69
31. D. Braida, S. Iosue, S. Pegorini, and M. Sala 3,4 Methylenedioxymethamphetamine-induced conditioned place preference (CPP) is mediated by endocannabinoid system Pharmacol Res 51 2005 177 182
32. D. Braida, M. Pozzi, R. Cavallini, and M. Sala Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system Neuroscience 104 2001 923 926
33. D. Braida, M. Pozzi, D. Parolaro, and M. Sala Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system Eur J Pharmacol 413 2001 227 234
34. D. Braida, and M. Sala Role of the endocannabinoid system in MDMA intracerebral self-administration in rats Br J Pharmacol 136 2002 1089 1092
35. R.T. Burkey, and J.R. Nation (R)-methanandamide, but not anandamide, substitutes for delta 9-THC in a drug-discrimination procedure Exp Clin Psychopharmacol 5 1997 195 202
36. G.A. Cabral, and L. Griffin-Thomas Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation Expert Rev Mol Med 11 2009 e3
37. S. Caille, L. Alvarez-Jaimes, I. Polis, D.G. Stouffer, and L.H. Parsons Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration J Neurosci 27 2007 3695 3702
38. S. Caillé, and L.H. Parsons SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats Eur J Neurosci 18 2003 3145 3149
39. S. Caille, and L.H. Parsons Cannabinoid modulation of opiate reinforcement through the ventral striatopallidal pathway Neuropsychopharmacology 31 2006 804 813
40. P. Campolongo, B. Roozendaal, V. Trezza, V. Cuomo, G. Astarita, and J. Fu Fat-induced satiety factor oleoylethanolamide enhances memory consolidation Proc Natl Acad Sci U S A 106 2009 8027 8031
41. B. Cariou, B. Charbonnel, and B. Staels Thiazolidinediones and PPARγ agonists: time for a reassessment Trends Endocrinol Metab 23 2012 205 215
42. A. Castane, F. Berrendero, and R. Maldonado The role of the cannabinoid system in nicotine addiction Pharmacol Biochem Behav 81 2005 381 386
43. CDC Smoking-attributable mortality, years of potential life lost, and productivity losses - United States, 2000-2004 MMWR Morb Mortal Wkly Rep 57 2008 1226 1228
44. V.A. Chakkarwar Fenofibrate attenuates nicotine-induced vascular endothelial dysfunction in the rat Vascul Pharmacol 55 2011 163 168
45. F. Chaperon, P. Soubrie, A.J. Puech, and M.H. Thiebot Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats Psychopharmacology (Berl) 135 1998 324 332
46. K.P. Chiang, A.L. Gerber, J.C. Sipe, and B.F. Cravatt Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use Hum Mol Genet 13 2004 2113 2119
47. R. Christensen, P.K. Kristensen, E.M. Bartels, H. Bliddal, and A. Astrup Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials Lancet 370 2007 1706 1713
48. A. Cippitelli, G. Astarita, A. Duranti, G. Caprioli, M. Ubaldi, and S. Stopponi Endocannabinoid regulation of acute and protracted nicotine withdrawal: effect of FAAH inhibition PLoS One 6 2011 e28142
49. A. Cippitelli, A. Bilbao, A.C. Hansson, I. del Arco, W. Sommer, and M. Heilig Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats Eur J Neurosci 21 2005 2243 2251
50. A. Cippitelli, N. Cannella, S. Braconi, A. Duranti, A. Tontini, and A. Bilbao Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat Psychopharmacology (Berl) 198 2008 449 460
51. J.R. Clapper, A. Duranti, A. Tontini, M. Mor, G. Tarzia, and D. Piomelli The fatty-acid amide hydrolase inhibitor URB597 does not affect triacylglycerol hydrolysis in rat tissues Pharmacol Res 54 2006 341 344
52. C. Cohen, G. Perrault, C. Voltz, R. Steinberg, and P. Soubrie SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats Behav Pharmacol 13 2002 451 463
53. G. Colombo, S. Serra, G. Brunetti, R. Gomez, S. Melis, and G. Vacca Stimulation of voluntary ethanol intake by cannabinoid receptor agonists in ethanol-preferring sP rats Psychopharmacology (Berl) 159 2002 181 187
54. D.E. Comings, D. Muhleman, R. Gade, P. Johnson, R. Verde, and G. Saucier Cannabinoid receptor gene (CNR1): association with i.v. drug use Mol Psychiatry 2 1997 161 168
55. A.G. Corbille, E. Valjent, G. Marsicano, C. Ledent, B. Lutz, and D. Herve Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants J Neurosci 27 2007 6937 6947
56. G. Cossu, C. Ledent, L. Fattore, A. Imperato, G.A. Bohme, and M. Parmentier Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse Behav Brain Res 118 2001 61 65
57. B. Costa, G. Giagnoni, and M. Colleoni Precipitated and spontaneous withdrawal in rats tolerant to anandamide Psychopharmacology (Berl) 149 2000 121 128
58. J. Covault, J. Gelernter, and H. Kranzler Association study of cannabinoid receptor gene (CNR1) alleles and drug dependence Mol Psychiatry 6 2001 501 502
59. J.C. Crabbe, T.J. Phillips, R.A. Harris, M.A. Arends, and G.F. Koob Alcohol-related genes: contributions from studies with genetically engineered mice Addict Biol 11 2006 195 269
60. B.F. Cravatt, K. Demarest, M.P. Patricelli, M.H. Bracey, D.K. Giang, and B.R. Martin Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase Proc Natl Acad Sci U S A 98 2001 9371 9376
61. B.F. Cravatt, D.K. Giang, S.P. Mayfield, D.L. Boger, R.A. Lerner, and N.B. Gilula Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides Nature 384 1996 83 87
62. J.L. Croxford Therapeutic potential of cannabinoids in CNS disease CNS Drugs 17 2003 179 202
63. M. Daza-Losada, J. Minarro, M.A. Aguilar, O. Valverde, and M. Rodriguez-Arias Acute blockade of CB1 receptor leads to reinstatement of MDMA-induced conditioned place preference Pharmacol Biochem Behav 100 2011 33 39
64. S.M. de la Monte, M. Pang, R. Chaudhry, K. Duan, L. Longato, and J. Carter Peroxisome proliferator-activated receptor agonist treatment of alcohol-induced hepatic insulin resistance Hepatol Res 41 2011 386 398
65. S.M. de la Monte, and J.R. Wands Role of central nervous system insulin resistance in fetal alcohol spectrum disorders J Popul Ther Clin Pharmacol 17 2010 e390 e404
66. T.J. De Vries, J.R. Homberg, R. Binnekade, H. Raaso, and A.N. Schoffelmeer Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats Psychopharmacology (Berl) 168 2003 164 169
67. T.J. De Vries, Y. Shaham, J.R. Homberg, H. Crombag, K. Schuurman, and J. Dieben A cannabinoid mechanism in relapse to cocaine seeking Nat Med 7 2001 1151 1154
68. M.S. Delatte, P.J. Winsauer, and J.M. Moerschbaecher Tolerance to the disruptive effects of delta(9)-THC on learning in rats Pharmacol Biochem Behav 74 2002 129 140
69. V. Di Marzo, F. Berrendero, T. Bisogno, S. Gonzalez, P. Cavaliere, and J. Romero Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9- tetrahydrocannabinol-tolerant rats J Neurochem 74 2000 1627 1635
70. V. Di Marzo, and M. Maccarrone FAAH and anandamide: is 2-AG really the odd one out? Trends Pharmacol Sci 29 2008 229 233
71. M. Dionisi, S.P. Alexander, and A.J. Bennett Oleamide activates peroxisome proliferator-activated receptor gamma (PPARgamma) in vitro Lipids Health Dis 11 2012 51
72. S.A. Eisenstein, P.V. Holmes, and A.G. Hohmann Endocannabinoid modulation of amphetamine sensitization is disrupted in a rodent model of lesion-induced dopamine dysregulation Synapse 63 2009 941 950
73. K.W. Falenski, A.J. Thorpe, J.E. Schlosburg, B.F. Cravatt, R.A. Abdullah, and T.H. Smith FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration Neuropsychopharmacology 35 2010 1775 1787
74. F. Fan, D.R. Compton, S. Ward, L. Melvin, and B.R. Martin Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212 J Pharmacol Exp Ther 271 1994 1383 1390
75. L. Fattore, G. Cossu, C.M. Martellotta, and W. Fratta Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats Psychopharmacology (Berl) 156 2001 410 416
76. L. Fattore, S. Deiana, S.M. Spano, G. Cossu, P. Fadda, and M. Scherma Endocannabinoid system and opioid addiction: behavioural aspects Pharmacol Biochem Behav 81 2005 343 359
77. L. Fattore, M.C. Martellotta, G. Cossu, M.S. Mascia, and W. Fratta CB1 cannabinoid receptor agonist WIN 55,212-2 decreases intravenous cocaine self-administration in rats Behav Brain Res 104 1999 141 146
78. L. Fattore, M.S. Spano, G. Cossu, S. Deiana, and W. Fratta Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats Eur J Neurosci 17 2003 1723 1726
79. I. Fedorova, A. Hashimoto, R.A. Fecik, M.P. Hedrick, L.O. Hanus, and D.L. Boger Behavioral evidence for the interaction of oleamide with multiple neurotransmitter systems J Pharmacol Exp Ther 299 2001 332 342
80. D. Fegley, S. Gaetani, A. Duranti, A. Tontini, M. Mor, and G. Tarzia Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation J Pharmacol Exp Ther 313 2005 352 358
81. J.R. Fernandez, and D.B. Allison Rimonabant Sanofi-Synthelabo Curr Opin Investig Drugs 5 2004 430 435
82. E. Fernandez-Espejo, S. Ramiro-Fuentes, and F. Rodriguez de Fonseca The absence of a functional peroxisome proliferator-activated receptor-alpha gene in mice enhances motor sensitizing effects of morphine, but not cocaine Neuroscience 164 2009 667 675
83. B. Ferrer, F.J. Bermudez-Silva, A. Bilbao, L. Alvarez-Jaimes, I. Sanchez-Vera, and A. Giuffrida Regulation of brain anandamide by acute administration of ethanol Biochem J 404 2007 97 104
84. F.M. Filbey, J.P. Schacht, U.S. Myers, R.S. Chavez, and K.E. Hutchison Individual and additive effects of the CNR1 and FAAH genes on brain response to marijuana cues Neuropsychopharmacology 35 2010 967 975
85. M. Filip, A. Golda, M. Zaniewska, A.C. McCreary, E. Nowak, and W. Kolasiewicz Involvement of cannabinoid CB1 receptors in drug addiction: effects of rimonabant on behavioral responses induced by cocaine Pharmacol Rep 58 2006 806 819
86. J.M. Flanagan, A.L. Gerber, J.L. Cadet, E. Beutler, and J.C. Sipe The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction Hum Genet 120 2006 581 588
87. B. Forget, K.M. Coen, and B. Le Foll Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration-comparison with CB(1) receptor blockade Psychopharmacology (Berl) 205 2009 613 624
88. T.F. Freund, I. Katona, and D. Piomelli Role of endogenous cannabinoids in synaptic signaling Physiol Rev 83 2003 1017 1066
89. J. Fu, G. Bottegoni, O. Sasso, R. Bertorelli, W. Rocchia, and M. Masetti A catalytically silent FAAH-1 variant drives anandamide transport in neurons Nat Neurosci 15 2012 64 69
90. J. Fu, S. Gaetani, F. Oveisi, J. Lo Verme, A. Serrano, and F. Rodriguez de Fonseca Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha Nature 425 2003 90 93
91. E.L. Gardner, W. Paredes, D. Smith, A. Donner, C. Milling, and D. Cohen Facilitation of brain stimulation reward by delta 9-tetrahydrocannabinol Psychopharmacology (Berl) 96 1988 142 144
92. L. Gelman, L. Michalik, B. Desvergne, and W. Wahli Kinase signaling cascades that modulate peroxisome proliferator-activated receptors Curr Opin Cell Biol 17 2005 216 222
93. G.L. Gessa, S. Serra, G. Vacca, M.A. Carai, and G. Colombo Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats Alcohol Alcohol 40 2005 46 53
94. S. Ghozland, H.W. Matthes, F. Simonin, D. Filliol, B.L. Kieffer, and R. Maldonado Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors J Neurosci 22 2002 1146 1154
95. D.K. Giang, and B.F. Cravatt Molecular characterization of human and mouse fatty acid amide hydrolases Proc Natl Acad Sci U S A 94 1997 2238 2242
96. C.K. Glass Going nuclear in metabolic and cardiovascular disease J Clin Invest 116 2006 556 560
97. M. Glass, and C.C. Felder Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor J Neurosci 17 1997 5327 5333
98. G. Gobbi, F.R. Bambico, R. Mangieri, M. Bortolato, P. Campolongo, and M. Solinas Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis Proc Natl Acad Sci U S A 102 2005 18620 18625
99. J. Godfrey Safety of therapeutic methylphenidate in adults: a systematic review of the evidence J Psychopharmacol 23 2009 194 205
100. G. Godlewski, S.O. Alapafuja, S. Batkai, S.P. Nikas, R. Cinar, and L. Offertaler Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects Chem Biol 17 2010 1256 1266
101. M. Gold, C. Alderton, M. Zvartau-Hind, S. Egginton, A.M. Saunders, and M. Irizarry Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study Dement Geriatr Cogn Disord 30 2010 131 146
102. S. Gonzalez, M.G. Cascio, J. Fernandez-Ruiz, F. Fezza, V. Di Marzo, and J.A. Ramos Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine Brain Res 954 2002 73 81
103. S. Gonzalez, J. Fernandez-Ruiz, V. Di Marzo, M. Hernandez, C. Arevalo, and C. Nicanor Behavioral and molecular changes elicited by acute administration of SR141716 to delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence Drug Alcohol Depend 74 2004 159 170
104. S. Gonzalez, P.C. Schmid, J. Fernandez-Ruiz, R. Krebsbach, H.H. Schmid, and J.A. Ramos Region-dependent changes in endocannabinoid transmission in the brain of morphine-dependent rats Addict Biol 8 2003 159 166
105. S. Gonzalez, M. Valenti, R. de Miguel, F. Fezza, J. Fernandez-Ruiz, and V. Di Marzo Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and their possible relevance to alcohol relapse Br J Pharmacol 143 2004 455 464
106. A.V. Goonawardena, J. Sesay, C.A. Sexton, G. Riedel, and R.E. Hampson Pharmacological elevation of anandamide impairs short-term memory by altering the neurophysiology in the hippocampus Neuropharmacology 61 2011 1016 1025
107. D.A. Gorelick, R.S. Goodwin, E. Schwilke, D.M. Schwope, W.D. Darwin, and D.L. Kelly Antagonist-elicited cannabis withdrawal in humans J Clin Psychopharmacol 31 2011 603 612
108. J. Guindon, and A.G. Hohmann Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain Br J Pharmacol 153 2008 319 334
109. O. Gunduz-Cinar, K.P. Macpherson, R. Cinar, J. Gamble-George, K. Sugden, and B. Williams Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity Mol Psychiatry 2012 10.1038/mp.2012.72
110. J. Haller, I. Barna, B. Barsvari, K. Gyimesi Pelczer, S. Yasar, and L.V. Panlilio Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats Psychopharmacology 204 2009 607 616
111. M. Haney, A.S. Ward, S.D. Comer, R.W. Foltin, and M.W. Fischman Abstinence symptoms following oral THC administration to humans Psychopharmacology (Berl) 141 1999 385 394
112. M. Haney, A.S. Ward, S.D. Comer, R.W. Foltin, and M.W. Fischman Abstinence symptoms following smoked marijuana in humans Psychopharmacology (Berl) 141 1999 395 404
113. A.C. Hansson, F.J. Bermudez-Silva, H. Malinen, P. Hyytia, I. Sanchez-Vera, and R. Rimondini Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference Neuropsychopharmacology 32 2007 117 126
114. H.M. Haughey, E. Marshall, J.P. Schacht, A. Louis, and K.E. Hutchison Marijuana withdrawal and craving: influence of the cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH) genes Addiction 103 2008 1678 1686
115. M.N. Hill, S.A. Kumar, S.B. Filipski, M. Iverson, K.L. Stuhr, and J.M. Keith Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure Mol Psychiatry 2012 10.1038/mp.2012.90
116. M.N. Hill, S. Patel, P. Campolongo, J.G. Tasker, C.T. Wotjak, and J.S. Bains Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output J Neurosci 30 2010 14980 14986
117. T. Hiranita, Y. Nawata, K. Sakimura, and T. Yamamoto Methamphetamine- seeking behavior is due to inhibition of nicotinic cholinergic transmission by activation of cannabinoid CB1 receptors Neuropharmacology 55 2008 1300 1306
118. A.C. Howlett Cannabinoid receptor signaling Handb Exp Pharmacol 168 2005 53 79
119. M.A. Huestis, S.J. Boyd, S.J. Heishman, K.L. Preston, D. Bonnet, and G. Le Fur Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users Psychopharmacology (Berl) 194 2007 505 515
120. M.A. Huestis, D.A. Gorelick, S.J. Heishman, K.L. Preston, R.A. Nelson, and E.T. Moolchan Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716 Arch Gen Psychiatry 58 2001 322 328
121. B.L. Hungund, I. Szakall, A. Adam, B.S. Basavarajappa, and C. Vadasz Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens J Neurochem 84 2003 698 704
122. D.M. Hutcheson, E.T. Tzavara, C. Smadja, E. Valjent, B.P. Roques, and J. Hanoune Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol Br J Pharmacol 125 1998 1567 1577
123. S. Ikemoto Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex Brain Res Rev 56 2007 27 78
124. H. Ishiguro, S. Iwasaki, L. Teasenfitz, S. Higuchi, Y. Horiuchi, and T. Saito Involvement of cannabinoid CB2 receptor in alcohol preference in mice and alcoholism in humans Pharmacogenomics J 7 2007 380 385
125. L. Iversen Cannabis and the brain Brain 126 2003 1252 1270
126. S. Iwasaki, H. Ishiguro, S. Higuchi, E.S. Onaivi, and T. Arinami Association study between alcoholism and endocannabinoid metabolic enzyme genes encoding fatty acid amide hydrolase and monoglyceride lipase in a Japanese population Psychiatr Genet 17 2007 215 220
127. T.U. Jarbe, R.J. Lamb, S. Lin, and A. Makriyannis (R)-methanandamide and delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide Psychopharmacology (Berl) 156 2001 369 380
128. T.U. Jarbe, R.J. Lamb, Q. Liu, and A. Makriyannis Discriminative stimulus functions of AM-1346, a CB1R selective anandamide analog in rats trained with delta9-THC or (R)-methanandamide (AM-356) Psychopharmacology (Berl) 188 2006 315 323
129. C. Jehl-Pietri, C. Bastie, I. Gillot, S. Luquet, and P.A. Grimaldi Peroxisome-proliferator-activated receptor delta mediates the effects of long-chain fatty acids on post-confluent cell proliferation Biochem J 350 Pt 1 2000 93 98
130. Z. Justinova, C. Barnes, S. Yasar, S.K. Vadivel, A. Makriyannis, and D. Piomelli Effects of modulation of endocannabinoid levels on the discriminative-stimulus effects of methamphetamine and cocaine in rats Neuroscience Meeting Planner San Diego, CA: Society for Neuroscience, 2007 Online Program No. 911.11 2007
131. Z. Justinova, S. Ferre, G.H. Redhi, P. Mascia, J. Stroik, and D. Quarta Reinforcing and neurochemical effects of cannabinoid CB1 receptor agonists, but not cocaine, are altered by an adenosine A2A receptor antagonist Addict Biol 16 2011 405 415
132. Z. Justinova, S.R. Goldberg, S.J. Heishman, and G. Tanda Self-administration of cannabinoids by experimental animals and human marijuana smokers Pharmacol Biochem Behav 81 2005 285 299
133. Z. Justinova, R.A. Mangieri, M. Bortolato, S.I. Chefer, A.G. Mukhin, and J.R. Clapper Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates Biol Psychiatry 64 2008 930 937
134. Z. Justinova, P. Munzar, L.V. Panlilio, S. Yasar, G.H. Redhi, and G. Tanda Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant Neuropsychopharmacology 33 2008 2870 2877
135. Z. Justinova, M. Solinas, G. Tanda, G.H. Redhi, and S.R. Goldberg The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys J Neurosci 25 2005 5645 5650
136. Z. Justinova, G. Tanda, P. Munzar, and S.R. Goldberg The opioid antagonist naltrexone reduces the reinforcing effects of delta 9 tetrahydrocannabinol (THC) in squirrel monkeys Psychopharmacology (Berl) 173 2004 186 194
137. Z. Justinova, G. Tanda, G.H. Redhi, and S.R. Goldberg Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys Psychopharmacology (Berl) 169 2003 135 140
138. Z. Justinova, S. Yasar, G.H. Redhi, and S.R. Goldberg The endogenous cannabinoid 2-arachidonoylglycerol is intravenously self-administered by squirrel monkeys J Neurosci 31 2011 7043 7048
139. M. Kaczocha, S.T. Glaser, and D.G. Deutsch Identification of intracellular carriers for the endocannabinoid anandamide Proc Natl Acad Sci U S A 106 2009 6375 6380
140. D.A. Karanian, Q.B. Brown, A. Makriyannis, T.A. Kosten, and B.A. Bahr Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity J Neurosci 25 2005 7813 7820
141. S. Kathuria, S. Gaetani, D. Fegley, F. Valino, A. Duranti, and A. Tontini Modulation of anxiety through blockade of anandamide hydrolysis Nat Med 9 2003 76 81
142. I. Katona, and T.F. Freund Endocannabinoid signaling as a synaptic circuit breaker in neurological disease Nat Med 14 2008 923 930
143. G.F. Koob Drugs of abuse: anatomy, pharmacology and function of reward pathways Trends Pharmacol Sci 13 1992 177 184
144. G.F. Koob Neural mechanisms of drug reinforcement Ann N Y Acad Sci 654 1992 171 191
145. T.R. Kosten, and T.P. George The neurobiology of opioid dependence: implications for treatment Sci Pract Perspect 1 2002 13 20
146. K.R. Kozak, R.A. Gupta, J.S. Moody, C. Ji, W.E. Boeglin, and R.N. DuBois 15-Lipoxygenase metabolism of 2-arachidonylglycerol. Generation of a peroxisome proliferator-activated receptor alpha agonist J Biol Chem 277 2002 23278 23286
147. F. Lallemand, and P. De Witte SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats Alcohol 39 2006 125 134
148. B. Le Foll, and S.R. Goldberg Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence J Pharmacol Exp Ther 312 2005 875 883
149. B. Le Foll, D.A. Gorelick, and S.R. Goldberg The future of endocannabinoid-oriented clinical research after CB1 antagonists Psychopharmacology (Berl) 205 2009 171 174
150. B. Le Foll, M. Wiggins, and S.R. Goldberg Nicotine pre-exposure does not potentiate the locomotor or rewarding effects of delta-9-tetrahydrocannabinol in rats Behav Pharmacol 17 2006 195 199
151. C. Ledent, O. Valverde, G. Cossu, F. Petitet, J.F. Aubert, and F. Beslot Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice Science 283 1999 401 404
152. J.D. Leggett, S. Aspley, S.R. Beckett, A.M. D'Antona, D.A. Kendall, and D.A. Kendall Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors Br J Pharmacol 141 2004 253 262
153. A. Lenman, and C.J. Fowler Interaction of ligands for the peroxisome proliferator-activated receptor gamma with the endocannabinoid system Br J Pharmacol 151 2007 1343 1351
154. M. Lepore, X. Liu, V. Savage, D. Matalon, and E.L. Gardner Genetic differences in delta 9-tetrahydrocannabinol-induced facilitation of brain stimulation reward as measured by a rate-frequency curve-shift electrical brain stimulation paradigm in three different rat strains Life Sci 58 1996 L365 L372
155. M. Lepore, S.R. Vorel, J. Lowinson, and E.L. Gardner Conditioned place preference induced by delta 9-tetrahydrocannabinol: comparison with cocaine, morphine, and food reward Life Sci 56 1995 2073 2080
156. H.M. Lesscher, E. Hoogveld, J.P. Burbach, J.M. van Ree, and M.A. Gerrits Endogenous cannabinoids are not involved in cocaine reinforcement and development of cocaine-induced behavioural sensitization Eur Neuropsychopharmacol 15 2005 31 37
157. X. Li, A.F. Hoffman, X.Q. Peng, C.R. Lupica, E.L. Gardner, and Z.X. Xi Attenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout mice Psychopharmacology (Berl) 204 2009 1 11
158. A.H. Lichtman, D. Leung, C.C. Shelton, A. Saghatelian, C. Hardouin, and D.L. Boger Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity J Pharmacol Exp Ther 311 2004 441 448
159. J. Lo Verme, J. Fu, G. Astarita, G. La Rana, R. Russo, and A. Calignano The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide Mol Pharmacol 67 2005 15 19
160. J. Lo Verme, G. La Rana, R. Russo, A. Calignano, and D. Piomelli The search for the palmitoylethanolamide receptor Life Sci 77 2005 1685 1698
161. J. Lo Verme, R. Russo, G. La Rana, J. Fu, J. Farthing, and G. Mattace-Raso Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha J Pharmacol Exp Ther 319 2006 1051 1061
162. J.Z. Long, D.K. Nomura, R.E. Vann, D.M. Walentiny, L. Booker, and X. Jin Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo Proc Natl Acad Sci U S A 106 2009 20270 20275
163. J.A. Lopez-Moreno, V. Echeverry-Alzate, and K.M. Buhler The genetic basis of the endocannabinoid system and drug addiction in humans J Psychopharmacol 26 2012 133 143
164. J.A. Lopez-Moreno, A. Lopez-Jimenez, M.A. Gorriti, and F. Rodriguez de Fonseca Functional interactions between endogenous cannabinoid and opioid systems: focus on alcohol, genetics and drug-addicted behaviors Curr Drug Targets 11 2010 406 428
165. D.M. Lovinger Presynaptic modulation by endocannabinoids Handb Exp Pharmacol 184 2008 435 477
166. A. Luchicchi, S. Lecca, S. Carta, G. Pillolla, A.L. Muntoni, and S. Yasar Effects of fatty acid amide hydrolase inhibition on neuronal responses to nicotine, cocaine and morphine in the nucleus accumbens shell and ventral tegmental area: involvement of PPAR-alpha nuclear receptors Addict Biol 15 2010 277 288
167. M. Luconi, G. Cantini, and M. Serio Peroxisome proliferator-activated receptor gamma (PPARgamma): is the genomic activity the only answer? Steroids 75 2010 585 594
168. M. Maccarrone, S. Rossi, M. Bari, V. De Chiara, F. Fezza, and A. Musella Anandamide inhibits metabolism and physiological actions of 2- arachidonoylglycerol in the striatum Nat Neurosci 11 2008 152 159
169. K. Mackie Distribution of cannabinoid receptors in the central and peripheral nervous system Handb Exp Pharmacol 168 2005 299 325
170. T. Maeda, N. Kiguchi, Y. Fukazawa, A. Yamamoto, M. Ozaki, and S. Kishioka Peroxisome proliferator-activated receptor gamma activation relieves expression of behavioral sensitization to methamphetamine in mice Neuropsychopharmacology 32 2007 1133 1140
171. R. Maldonado, and F. Berrendero Endogenous cannabinoid and opioid systems and their role in nicotine addiction Curr Drug Targets 11 2010 440 449
172. R. Maldonado, and F. Rodriguez de Fonseca Cannabinoid addiction: behavioral models and neural correlates J Neurosci 22 2002 3326 3331
173. R. Maldonado, O. Valverde, and F. Berrendero Involvement of the endocannabinoid system in drug addiction Trends Neurosci 29 2006 225 232
174. P.E. Mallet, and R.J. Beninger Delta9-tetrahydrocannabinol, but not the endogenous cannabinoid receptor ligand anandamide, produces conditioned place avoidance Life Sci 62 1998 2431 2439
175. S. Mandrekar-Colucci, and G.E. Landreth Nuclear receptors as therapeutic targets for Alzheimer's disease Expert Opin Ther Targets 15 2011 1085 1097
176. H.D. Mansvelder, and D.S. McGehee Cellular and synaptic mechanisms of nicotine addiction J Neurobiol 53 2002 606 617
177. L.A. Manwell, E. Satvat, S.T. Lang, C.P. Allen, F. Leri, and L.A. Parker FAAH inhibitor, URB-597, promotes extinction and CB(1) antagonist, SR141716, inhibits extinction of conditioned aversion produced by naloxone-precipitated morphine withdrawal, but not extinction of conditioned preference produced by morphine in rats Pharmacol Biochem Behav 94 2009 154 162
178. C. Manzanedo, M. Rodriguez-Arias, M. Daza-Losada, C. Maldonado, M.A. Aguilar, and J. Minarro Effect of the CB1 cannabinoid agonist WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference in mice Behav Brain Funct 6 2010 19
179. K. Marche, T. Danel, and R. Bordet Fetal alcohol-induced hyperactivity is reversed by treatment with the PPARalpha agonist fenofibrate in a rat model Psychopharmacology (Berl) 214 2011 285 296
180. G. Marsicano, C.T. Wotjak, S.C. Azad, T. Bisogno, G. Rammes, and M.G. Cascio The endogenous cannabinoid system controls extinction of aversive memories Nature 418 2002 530 534
181. M.C. Martellotta, G. Cossu, L. Fattore, G.L. Gessa, and W. Fratta Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice Neuroscience 85 1998 327 330
182. B.R. Martin Role of lipids and lipid signaling in the development of cannabinoid tolerance Life Sci 77 2005 1543 1558
183. M. Martin, C. Ledent, M. Parmentier, R. Maldonado, and O. Valverde Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice Eur J Neurosci 12 2000 4038 4046
184. P. Mascia, M. Pistis, Z. Justinova, L.V. Panlilio, A. Luchicchi, and S. Lecca Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors Biol Psychiatry 69 2011 633 641
185. I. Matias, M.P. Gonthier, P. Orlando, V. Martiadis, L. De Petrocellis, and C. Cervino Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia J Clin Endocrinol Metab 91 2006 3171 3180
186. H. Matsuura, H. Adachi, R.C. Smart, X. Xu, J. Arata, and A.M. Jetten Correlation between expression of peroxisome proliferator-activated receptor beta and squamous differentiation in epidermal and tracheobronchial epithelial cells Mol Cell Endocrinol 147 1999 85 92
187. C. Mazzola, J. Medalie, M. Scherma, L.V. Panlilio, M. Solinas, and G. Tanda Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-alpha nuclear receptors Learn Mem 16 2009 332 337
188. A.L. McCallum, C.L. Limebeer, and L.A. Parker Reducing endocannabinoid metabolism with the fatty acid amide hydrolase inhibitor, URB597, fails to modify reinstatement of morphine-induced conditioned floor preference and naloxone-precipitated morphine withdrawal-induced conditioned floor avoidance Pharmacol Biochem Behav 96 2010 496 500
189. D.L. McKinney, M.P. Cassidy, L.M. Collier, B.R. Martin, J.L. Wiley, and D.E. Selley Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9- tetrahydrocannabinol J Pharmacol Exp Ther 324 2008 664 673
190. P.J. McLaughlin, K. Winston, L. Swezey, A. Wisniecki, J. Aberman, and D.J. Tardif The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats Behav Pharmacol 14 2003 583 588
191. L.R. McMahon Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating delta9-tetrahydrocannabinol J Pharmacol Exp Ther 319 2006 1211 1218
192. L.R. McMahon Apparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of anandamide in rhesus monkeys discriminating delta9-tetrahydrocannabinol Psychopharmacology (Berl) 203 2009 219 228
193. L.R. McMahon Chronic delta-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids Br J Pharmacol 162 2011 1060 1073
194. L.R. McMahon, B.C. Ginsburg, and R.J. Lamb Cannabinoid agonists differentially substitute for the discriminative stimulus effects of delta(9)-tetrahydrocannabinol in C57BL/6J mice Psychopharmacology (Berl) 198 2008 487 495
195. R. Mechoulam, E. Fride, and V. Di Marzo Endocannabinoids Eur J Pharmacol 359 1998 1 18
196. M. Melis, S. Carta, L. Fattore, S. Tolu, S. Yasar, and S.R. Goldberg Peroxisome proliferator-activated receptors-alpha modulate dopamine cell activity through nicotinic receptors Biol Psychiatry 68 2010 256 264
197. M. Melis, G. Pillolla, A. Luchicchi, A.L. Muntoni, S. Yasar, and S.R. Goldberg Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors J Neurosci 28 2008 13985 13994
198. M. Melis, M. Pistis, S. Perra, A.L. Muntoni, G. Pillolla, and G.L. Gessa Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors J Neurosci 24 2004 53 62
199. L.L. Merritt, B.R. Martin, C. Walters, A.H. Lichtman, and M.I. Damaj The endogenous cannabinoid system modulates nicotine reward and dependence J Pharmacol Exp Ther 326 2008 483 492
200. S. Moreno, S. Farioli-Vecchioli, and M.P. Ceru Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS Neuroscience 123 2004 131 145
201. Y. Morita, H. Ujike, Y. Tanaka, N. Uchida, A. Nomura, and K. Ohtani A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia Neurosci Lett 376 2005 182 187
202. P.P. Muldoon, A.H. Lichtman, L.H. Parsons, and M.I. Damaj The role of fatty acid amide hydrolase inhibition in nicotine reward and dependence Life Sci 2012 10.1016/j.lfs.2012.05.015
203. E. Murillo-Rodriguez, M. Giordano, R. Cabeza, S.J. Henriksen, M. Mendez Diaz, and L. Navarro Oleamide modulates memory in rats Neurosci Lett 313 2001 61 64
204. A. Nakajima, K. Yamada, T. Nagai, T. Uchiyama, Y. Miyamoto, and T. Mamiya Role of tumor necrosis factor-alpha in methamphetamine-induced drug dependence and neurotoxicity J Neurosci 24 2004 2212 2225
205. M. Navarro, M.R. Carrera, W. Fratta, O. Valverde, G. Cossu, and L. Fattore Functional interaction between opioid and cannabinoid receptors in drug self-administration J Neurosci 21 2001 5344 5350
206. M. Navarro, J. Chowen, M.R. Carrera, I. del Arco, M.A. Villanua, and Y. Martin CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats Neuroreport 9 1998 3397 3402
207. E.J. Nestler Genes and addiction Nat Genet 26 2000 277 281
208. E.S. Onaivi, H. Ishiguro, S. Gu, and Q.R. Liu CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity J Psychopharmacol 26 2012 92 103
209. E.S. Onaivi, H. Ishiguro, P. Sejal, P.A. Meozzi, L. Myers, and P. Tagliaferro Methods to study the behavioral effects and expression of CB2 cannabinoid receptor and its gene transcripts in the chronic mild stress model of depression Methods Mol Med 123 2006 291 298
210. L. Orio, S. Edwards, O. George, L.H. Parsons, and G.F. Koob A role for the endocannabinoid system in the increased motivation for cocaine in extended-access conditions J Neurosci 29 2009 4846 4857
211. S. Ortiz, J.M. Oliva, S. Perez-Rial, T. Palomo, and J. Manzanares Differences in basal cannabinoid CB1 receptor function in selective brain areas and vulnerability to voluntary alcohol consumption in Fawn Hooded and Wistar rats Alcohol Alcohol 39 2004 297 302
212. S.E. O'Sullivan Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors Br J Pharmacol 152 2007 576 582
213. S.E. O'Sullivan, and D.A. Kendall Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease Immunobiology 215 2010 611 616
214. S.E. O'Sullivan, D.A. Kendall, and M.D. Randall Time-dependent vascular effects of endocannabinoids mediated by peroxisome proliferator-activated receptor gamma (PPARgamma) PPAR Res 2009 2009 425289
215. S.E. O'Sullivan, E.J. Tarling, A.J. Bennett, D.A. Kendall, and M.D. Randall Novel time-dependent vascular actions of delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma Biochem Biophys Res Commun 337 2005 824 831
216. B. Pan, W. Wang, P. Zhong, J.L. Blankman, B.F. Cravatt, and Q.S. Liu Alterations of endocannabinoid signaling, synaptic plasticity, learning, and memory in monoacylglycerol lipase knock-out mice J Neurosci 31 2011 13420 13430
217. L.V. Panlilio, Z. Justinova, P. Mascia, M. Pistis, A. Luchicchi, and S. Lecca Novel use of a lipid-lowering fibrate medication to prevent nicotine reward and relapse: preclinical findings Neuropsychopharmacology 37 2012 1838 1847
218. S. Perra, G. Pillolla, M. Melis, A.L. Muntoni, G.L. Gessa, and M. Pistis Involvement of the endogenous cannabinoid system in the effects of alcohol in the mesolimbic reward circuit: electrophysiological evidence in vivo Psychopharmacology (Berl) 183 2005 368 377
219. R.G. Pertwee Pharmacological actions of cannabinoids Handb Exp Pharmacol 168 2005 1 51
220. R.G. Pertwee Cannabinoid pharmacology: the first 66 years Br J Pharmacol 147 Suppl. 1 2006 S163 S171
221. R.G. Pertwee, A.C. Howlett, M.E. Abood, S.P. Alexander, V. Di Marzo, and M.R. Elphick International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2) Pharmacol Rev 62 2010 588 631
222. S. Petrosino, and V. Di Marzo FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels Curr Opin Investig Drugs 11 2010 51 62
223. D. Piomelli The molecular logic of endocannabinoid signalling Nat Rev Neurosci 4 2003 873 884
224. D. Piomelli, G. Tarzia, A. Duranti, A. Tontini, M. Mor, and T.R. Compton Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597) CNS Drug Rev 12 2006 21 38
225. M. Pistis, and M. Melis From surface to nuclear receptors: the endocannabinoid family extends its assets Curr Med Chem 17 2010 1450 1467
226. A. Plaza-Zabala, F. Berrendero, J. Suarez, F.J. Bermudez-Silva, E. Fernandez-Espejo, and A. Serrano Effects of the endogenous PPAR-alpha agonist, oleoylethanolamide on MDMA-induced cognitive deficits in mice Synapse 64 2010 379 389
227. A.C. Porter, and C.C. Felder The endocannabinoid nervous system: unique opportunities for therapeutic intervention Pharmacol Ther 90 2001 45 60
228. M.R. Price, G.L. Baillie, A. Thomas, L.A. Stevenson, M. Easson, and R. Goodwin Allosteric modulation of the cannabinoid CB1 receptor Mol Pharmacol 68 2005 1484 1495
229. D. Proudnikov, T. Kroslak, J.C. Sipe, M. Randesi, D. Li, and S. Hamon Association of polymorphisms of the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes with heroin addiction: impact of long repeats of CNR1 Pharmacogenomics J 10 2010 232 242
230. D. Ramesh, G.R. Ross, J.E. Schlosburg, R.A. Owens, R.A. Abdullah, and S.G. Kinsey Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice J Pharmacol Exp Ther 339 2011 173 185
231. O.V. Rice, N. Gordon, and A.N. Gifford Conditioned place preference to morphine in cannabinoid CB1 receptor knockout mice Brain Res 945 2002 135 138
232. A.C. Riegel, and C.R. Lupica Independent presynaptic and postsynaptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area J Neurosci 24 2004 11070 11078
233. R. Rimondini, C. Arlinde, W. Sommer, and M. Heilig Long-lasting increase in voluntary ethanol consumption and transcriptional regulation in the rat brain after intermittent exposure to alcohol FASEB J 16 2002 27 35
234. M. Rinaldi-Carmona, F. Barth, M. Heaulme, D. Shire, B. Calandra, and C. Congy SR141716A, a potent and selective antagonist of the brain cannabinoid receptor FEBS Lett 350 1994 240 244
235. D. Robbe, M. Kopf, A. Remaury, J. Bockaert, and O.J. Manzoni Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens Proc Natl Acad Sci U S A 99 2002 8384 8388
236. T.E. Robinson, and K.C. Berridge The neural basis of drug craving: an incentive-sensitization theory of addiction Brain Res Brain Res Rev 18 1993 247 291
237. C.E. Rockwell, and N.E. Kaminski A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes J Pharmacol Exp Ther 311 2004 683 690
238. F. Rodriguez de Fonseca, I. del Arco, F.J. Bermudez-Silva, A. Bilbao, A. Cippitelli, and M. Navarro The endocannabinoid system: physiology and pharmacology Alcohol Alcohol 40 2005 2 14
239. F. Rodriguez de Fonseca, M.A. Gorriti, J.J. Fernandez-Ruiz, T. Palomo, and J.A. Ramos Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment Pharmacol Biochem Behav 47 1994 33 40
240. J.S. Rodriguez, S.Y. Boctor, L.C. Flores, C.F. Phelix, and J.L. Martinez Jr. Local pretreatment with the cannabinoid CB1 receptor antagonist AM251 attenuates methamphetamine intra-accumbens self-administration Neurosci Lett 489 2011 187 191
241. T. Rubino, G. Forlani, D. Vigano, R. Zippel, and D. Parolaro Modulation of extracellular signal-regulated kinases cascade by chronic delta 9-tetrahydrocannabinol treatment Mol Cell Neurosci 25 2004 355 362
242. T. Rubino, G. Forlani, D. Vigano, R. Zippel, and D. Parolaro Ras/ERK signalling in cannabinoid tolerance: from behaviour to cellular aspects J Neurochem 93 2005 984 991
243. T. Rubino, D. Vigano, P. Massi, and D. Parolaro Changes in the cannabinoid receptor binding, G protein coupling, and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55,940 J Neurochem 75 2000 2080 2086
244. T. Rubino, D. Vigano, P. Massi, M. Spinello, E. Zagato, and G. Giagnoni Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions Neuropharmacology 39 2000 1331 1336
245. M. Rubio, R. de Miguel, J. Fernandez-Ruiz, D. Gutierrez-Lopez, M.A. Carai, and J.A. Ramos Effects of a short-term exposure to alcohol in rats on FAAH enzyme and CB1 receptor in different brain areas Drug Alcohol Depend 99 2009 354 358
246. M. Rubio, D. McHugh, J. Fernandez-Ruiz, H. Bradshaw, and J.M. Walker Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol Neurosci Lett 421 2007 270 274
247. D. Rucker, R. Padwal, S.K. Li, C. Curioni, and D.C. Lau Long term pharmacotherapy for obesity and overweight: updated meta-analysis BMJ 335 2007 1194 1199
248. A. Saghatelian, M.K. McKinney, M. Bandell, A. Patapoutian, and B.F. Cravatt A FAAH-regulated class of N-acyl taurines that activates TRP ion channels Biochemistry 45 2006 9007 9015
249. I. Saluja, J.G. Granneman, and R.P. Skoff PPAR delta agonists stimulate oligodendrocyte differentiation in tissue culture Glia 33 2001 191 204
250. J.P. Schacht, R.E. Selling, and K.E. Hutchison Intermediate cannabis dependence phenotypes and the FAAH C385A variant: an exploratory analysis Psychopharmacology (Berl) 203 2009 511 517
251. M. Scherma, P. Fadda, B. Le Foll, B. Forget, W. Fratta, and S.R. Goldberg The endocannabinoid system: a new molecular target for the treatment of tobacco addiction CNS Neurol Disord Drug Targets 7 2008 468 481
252. M. Scherma, J. Medalie, W. Fratta, S.K. Vadivel, A. Makriyannis, and D. Piomelli The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition Neuropharmacology 54 2008 129 140
253. M. Scherma, L.V. Panlilio, P. Fadda, L. Fattore, I. Gamaleddin, and B. Le Foll Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3′-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats J Pharmacol Exp Ther 327 2008 482 490
254. C.W. Schindler, L.V. Panlilio, J.P. Gilman, Z. Justinova, V.K. Vemuri, and A. Makriyannis Effects of cannabinoid receptor antagonists on maintenance and reinstatement of methamphetamine self-administration in rhesus monkeys Eur J Pharmacol 633 2010 44 49
255. E. Schlicker, and M. Kathmann Modulation of transmitter release via presynaptic cannabinoid receptors Trends Pharmacol Sci 22 2001 565 572
256. J.E. Schlosburg, B.L. Carlson, D. Ramesh, R.A. Abdullah, J.Z. Long, and B.F. Cravatt Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice AAPS J 11 2009 342 352
257. J.E. Schlosburg, S.G. Kinsey, and A.H. Lichtman Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation AAPS J 11 2009 39 44
258. A. Seillier, T. Advani, T. Cassano, J.G. Hensler, and A. Giuffrida Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats Int J Neuropsychopharmacol 13 2010 373 386
259. A. Serrano, and L.H. Parsons Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors Pharmacol Ther 132 2011 215 241
260. S. Shahidi, and P. Hasanein Behavioral effects of fatty acid amide hydrolase inhibition on morphine withdrawal symptoms Brain Res Bull 86 2011 118 122
261. U. Shalev, S. Erb, and Y. Shaham Role of CRF and other neuropeptides in stress-induced reinstatement of drug seeking Brain Res 1314 2010 15 28
262. T.S. Shippenberg, and G.I. Elmer The neurobiology of opiate reinforcement Crit Rev Neurobiol 12 1998 267 303
263. H. Singh, D.R. Schulze, and L.R. McMahon Tolerance and cross-tolerance to cannabinoids in mice: schedule-controlled responding and hypothermia Psychopharmacology (Berl) 215 2011 665 675
264. M.E. Singh, A.N. Verty, I.S. McGregor, and P.E. Mallet A cannabinoid receptor antagonist attenuates conditioned place preference but not behavioural sensitization to morphine Brain Res 1026 2004 244 253
265. J.C. Sipe, K. Chiang, A.L. Gerber, E. Beutler, and B.F. Cravatt A missense mutation in human fatty acid amide hydrolase associated with problem drug use Proc Natl Acad Sci U S A 99 2002 8394 8399
266. P.B. Smith, D.R. Compton, S.P. Welch, R.K. Razdan, R. Mechoulam, and B.R. Martin The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice J Pharmacol Exp Ther 270 1994 219 227
267. M. Solinas, Z. Justinova, S.R. Goldberg, and G. Tanda Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats J Neurochem 98 2006 408 419
268. M. Solinas, L.V. Panlilio, K. Antoniou, L.A. Pappas, and S.R. Goldberg The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats J Pharmacol Exp Ther 306 2003 93 102
269. M. Solinas, L.V. Panlilio, G. Tanda, A. Makriyannis, S.A. Matthews, and S.R. Goldberg Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats Neuropsychopharmacology 30 2005 2046 2057
270. M. Solinas, G. Tanda, Z. Justinova, C.E. Wertheim, S. Yasar, and D. Piomelli The endogenous cannabinoid anandamide produces delta-9- tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport J Pharmacol Exp Ther 321 2007 370 380
271. G. Soria, V. Mendizabal, C. Tourino, P. Robledo, C. Ledent, and M. Parmentier Lack of CB1 cannabinoid receptor impairs cocaine self-administration Neuropsychopharmacology 30 2005 1670 1680
272. M.S. Spano, L. Fattore, G. Cossu, S. Deiana, P. Fadda, and W. Fratta CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat Br J Pharmacol 143 2004 343 350
273. J.L. Stewart, and L.R. McMahon The fatty acid amide hydrolase inhibitor URB 597: interactions with anandamide in rhesus monkeys Br J Pharmacol 164 2011 655 666
274. S. Stopponi, L. Somaini, A. Cippitelli, N. Cannella, S. Braconi, and M. Kallupi Activation of nuclear PPARgamma receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking Biol Psychiatry 69 2011 642 649
275. Y. Sun, S.P. Alexander, M.J. Garle, C.L. Gibson, K. Hewitt, and S.P. Murphy Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism Br J Pharmacol 152 2007 734 743
276. Y. Sun, S.P. Alexander, D.A. Kendall, and A.J. Bennett Cannabinoids and PPARalpha signalling Biochem Soc Trans 34 2006 1095 1097
277. Y. Sun, and A. Bennett Cannabinoids: a new group of agonists of PPARs PPAR Res 2007 2007 23513
278. A. Suzuki, S.A. Josselyn, P.W. Frankland, S. Masushige, A.J. Silva, and S. Kida Memory reconsolidation and extinction have distinct temporal and biochemical signatures J Neurosci 24 2004 4787 4795
279. B. Szabo, and E. Schlicker Effects of cannabinoids on neurotransmission Handb Exp Pharmacol 168 2005 327 365
280. G. Tanda, and S.R. Goldberg Cannabinoids: reward, dependence, and underlying neurochemical mechanisms - a review of recent preclinical data Psychopharmacology (Berl) 169 2003 115 134
281. G. Tanda, P. Munzar, and S.R. Goldberg Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys Nat Neurosci 3 2000 1073 1074
282. G. Tanda, F.E. Pontieri, and G. Di Chiara Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism Science 276 1997 2048 2050
283. D.A. Taylor, and M.R. Fennessy Time-course of the effects of chronic delta 9-tetrahydrocannabinol on behaviour, body temperature, brain amines and withdrawal-like behaviour in the rat J Pharm Pharmacol 34 1982 240 245
284. D. Taylor, N. Meader, V. Bird, S. Pilling, F. Creed, and D. Goldberg Pharmacological interventions for people with depression and chronic physical health problems: systematic review and meta-analyses of safety and efficacy Br J Psychiatry 198 2011 179 188
285. P.K. Thanos, E.S. Dimitrakakis, O. Rice, A. Gifford, and N.D. Volkow Ethanol self-administration and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB1 receptors Behav Brain Res 164 2005 206 213
286. G. Thiemann, M. van der Stelt, S. Petrosino, A. Molleman, V. Di Marzo, and R.U. Hasenohrl The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization Behav Brain Res 187 2008 289 296
287. E. Torres, M.D. Gutierrez-Lopez, E. Borcel, I. Peraile, A. Mayado, and E. O'Shea Evidence that MDMA (E-14) increases cannabinoid CB2 receptor expression in microglial cells: role in the neuroinflammatory response in rat brain J Neurochem 113 2010 67 78
288. C. Tourino, C. Ledent, R. Maldonado, and O. Valverde CB1 cannabinoid receptor modulates 3,4-methylenedioxymethamphetamine acute responses and reinforcement Biol Psychiatry 63 2008 1030 1038
289. T. Tsuji, M. Asanuma, I. Miyazaki, K. Miyoshi, and N. Ogawa Reduction of nuclear peroxisome proliferator-activated receptor gamma expression in methamphetamine-induced neurotoxicity and neuroprotective effects of ibuprofen Neurochem Res 34 2009 764 774
290. R.F. Tyndale, J.I. Payne, A.L. Gerber, and J.C. Sipe The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: studies of drug use and dependence in Caucasians Am J Med Genet B Neuropsychiatr Genet 144B 2007 660 666
291. T.M. Tzschentke Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade Addict Biol 12 2007 227 462
292. E. Valjent, and R. Maldonado A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol in mice Psychopharmacology (Berl) 147 2000 436 438
293. S. Vandevoorde Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors Curr Top Med Chem 8 2008 247 267
294. R.E. Vann, D.M. Walentiny, J.J. Burston, K.M. Tobey, T.F. Gamage, and J.L. Wiley Enhancement of the behavioral effects of endogenous and exogenous cannabinoid agonists by phenylmethyl sulfonyl fluoride Neuropharmacology 62 2012 1019 1027
295. R.E. Vann, J.A. Warner, K. Bushell, J.W. Huffman, B.R. Martin, and J.L. Wiley Discriminative stimulus properties of delta9-tetrahydrocannabinol (THC) in C57Bl/6J mice Eur J Pharmacol 615 2009 102 107
296. T. Varga, Z. Czimmerer, and L. Nagy PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation Biochim Biophys Acta 1812 2011 1007 1022
297. S.A. Varvel, E.A. Anum, and A.H. Lichtman Disruption of CB(1) receptor signaling impairs extinction of spatial memory in mice Psychopharmacology (Berl) 179 2005 863 872
298. S.A. Varvel, B.F. Cravatt, A.E. Engram, and A.H. Lichtman Fatty acid amide hydrolase (-/-) mice exhibit an increased sensitivity to the disruptive effects of anandamide or oleamide in a working memory water maze task J Pharmacol Exp Ther 317 2006 251 257
299. S.A. Varvel, L.E. Wise, F. Niyuhire, B.F. Cravatt, and A.H. Lichtman Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task Neuropsychopharmacology 32 2007 1032 1041
300. V. Vengeliene, A. Bilbao, A. Molander, and R. Spanagel Neuropharmacology of alcohol addiction Br J Pharmacol 154 2008 299 315
301. A.J. Verberne, D.A. Taylor, and M.R. Fennessy Attenuation of delta 9-tetrahydrocannabinol-induced withdrawal-like behaviour by delta 9-tetrahydrocannabinol Psychopharmacology (Berl) 73 1981 97 98
302. D. Vigano, M.G. Cascio, T. Rubino, F. Fezza, A. Vaccani, and V. Di Marzo Chronic morphine modulates the contents of the endocannabinoid, 2-arachidonoyl glycerol, in rat brain Neuropsychopharmacology 28 2003 1160 1167
303. D. Vigano, M. Valenti, M.G. Cascio, V. Di Marzo, D. Parolaro, and T. Rubino Changes in endocannabinoid levels in a rat model of behavioural sensitization to morphine Eur J Neurosci 20 2004 1849 1857
304. J. Vinklerova, J. Novakova, and A. Sulcova Inhibition of methamphetamine self-administration in rats by cannabinoid receptor antagonist AM 251 J Psychopharmacol 16 2002 139 143
305. K.Y. Vinod, S.A. Kassir, B.L. Hungund, T.B. Cooper, J.J. Mann, and V. Arango Selective alterations of the CB1 receptors and the fatty acid amide hydrolase in the ventral striatum of alcoholics and suicides J Psychiatr Res 44 2010 591 597
306. K.Y. Vinod, E. Sanguino, R. Yalamanchili, J. Manzanares, and B.L. Hungund Manipulation of fatty acid amide hydrolase functional activity alters sensitivity and dependence to ethanol J Neurochem 104 2008 233 243
307. K.Y. Vinod, R. Yalamanchili, S. Xie, T.B. Cooper, and B.L. Hungund Effect of chronic ethanol exposure and its withdrawal on the endocannabinoid system Neurochem Int 49 2006 619 625
308. S. Vlachou, G.G. Nomikos, and G. Panagis WIN 55,212-2 decreases the reinforcing actions of cocaine through CB1 cannabinoid receptor stimulation Behav Brain Res 141 2003 215 222
309. S. Vlachou, G.G. Nomikos, and G. Panagis CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat Psychopharmacology (Berl) 179 2005 498 508
310. S. Vlachou, G.G. Nomikos, and G. Panagis Effects of endocannabinoid neurotransmission modulators on brain stimulation reward Psychopharmacology (Berl) 188 2006 293 305
311. S. Vlachou, G.G. Nomikos, D.N. Stephens, and G. Panagis Lack of evidence for appetitive effects of delta 9-tetrahydrocannabinol in the intracranial self-stimulation and conditioned place preference procedures in rodents Behav Pharmacol 18 2007 311 319
312. D.M. Walentiny, T.F. Gamage, J.A. Warner, T.K. Nguyen, D.B. Grainger, and J.L. Wiley The endogenous cannabinoid anandamide shares discriminative stimulus effects with (9)-tetrahydrocannabinol in fatty acid amide hydrolase knockout mice Eur J Pharmacol 656 2011 63 67
313. S.J. Ward, M. Rosenberg, L.A. Dykstra, and E.A. Walker The CB1 antagonist rimonabant (SR141716) blocks cue-induced reinstatement of cocaine seeking and other context and extinction phenomena predictive of relapse Drug Alcohol Depend 105 2009 248 255
314. B.Q. Wei, T.S. Mikkelsen, M.K. McKinney, E.S. Lander, and B.F. Cravatt A second fatty acid amide hydrolase with variable distribution among placental mammals J Biol Chem 281 2006 36569 36578
315. J.L. Wiley, R. Balster, and B. Martin Discriminative stimulus effects of anandamide in rats Eur J Pharmacol 276 1995 49 54
316. J.L. Wiley, R.L. Barrett, R.L. Balster, and B.R. Martin Tolerance to the discriminative stimulus effects of delta(9)-tetrahydrocannabinol Behav Pharmacol 4 1993 581 585
317. J.L. Wiley, K.M. Golden, W.J. Ryan, R.L. Balster, R.K. Razdan, and B.R. Martin Evaluation of cannabimimetic discriminative stimulus effects of anandamide and methylated fluoroanandamide in rhesus monkeys Pharmacol Biochem Behav 58 1997 1139 1143
318. J.L. Wiley, J.W. Huffman, R.L. Balster, and B.R. Martin Pharmacological specificity of the discriminative stimulus effects of delta 9- tetrahydrocannabinol in rhesus monkeys Drug Alcohol Depend 40 1995 81 86
319. J.L. Wiley, K.L. LaVecchia, N.E. Karp, S. Kulasegram, A. Mahadevan, and R.K. Razdan A comparison of the discriminative stimulus effects of delta(9)-tetrahydrocannabinol and O-1812, a potent and metabolically stable anandamide analog, in rats Exp Clin Psychopharmacol 12 2004 173 179
320. J.L. Wiley, J.A. Lowe, R.L. Balster, and B.R. Martin Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys J Pharmacol Exp Ther 275 1995 1 6
321. J.L. Wiley, W.J. Ryan, R.K. Razdan, and B.R. Martin Evaluation of cannabimimetic effects of structural analogs of anandamide in rats Eur J Pharmacol 355 1998 113 118
322. R.A. Wise Dopamine, learning and motivation Nat Rev Neurosci 5 2004 483 494
323. L.E. Wise, J.P. Harloe, and A.H. Lichtman Fatty acid amide hydrolase (FAAH) knockout mice exhibit enhanced acquisition of an aversive, but not of an appetitive, Barnes maze task Neurobiol Learn Mem 92 2009 597 601
324. Z.X. Xi, J.G. Gilbert, X.Q. Peng, A.C. Pak, X. Li, and E.L. Gardner Cannabinoid CB1 receptor antagonist AM251 inhibits cocaine-primed relapse in rats: role of glutamate in the nucleus accumbens J Neurosci 26 2006 8531 8536
325. Z.X. Xi, X.Q. Peng, X. Li, R. Song, H.Y. Zhang, and Q.R. Liu Brain cannabinoid CB receptors modulate cocaine's actions in mice Nat Neurosci 14 2011 1160 1166
326. Z.X. Xi, K. Spiller, A.C. Pak, J. Gilbert, C. Dillon, and X. Li Cannabinoid CB1 receptor antagonists attenuate cocaine's rewarding effects: experiments with self-administration and brain-stimulation reward in rats Neuropsychopharmacology 33 2008 1735 1745
327. S. Zalcman, I. Savina, and R.A. Wise Interleukin-6 increases sensitivity to the locomotor-stimulating effects of amphetamine in rats Brain Res 847 1999 276 283
328. C. Zanettini, L.V. Panlilio, M. Aliczki, S.R. Goldberg, J. Haller, and S. Yasar Effects of endocannabinoid system modulation on cognitive and emotional behavior Front Behav Neurosci 5 2011 57
329. A. Zangen, M. Solinas, S. Ikemoto, S.R. Goldberg, and R.A. Wise Two brain sites for cannabinoid reward J Neurosci 26 2006 4901 4907
330. P.W. Zhang, H. Ishiguro, T. Ohtsuki, J. Hess, F. Carillo, and D. Walther Human cannabinoid receptor 1: 5′ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse Mol Psychiatry 9 2004 916 931
331. L. Zuo, H.R. Kranzler, X. Luo, J. Covault, and J. Gelernter CNR1 variation modulates risk for drug and alcohol dependence Biol Psychiatry 62 2007 616 626